UCSF Multiple Sclerosis Center

tel: (415) 353-2069 fax: (415 353-2633 1500 Owens Street, Suite 320 San Francisco, CA 94158 **UCSF** Medical Center

Teriflunomide (Aubagio)

Patient Information

This information is for educational purposes only and is not intended to replace the advice of your doctor or health care provider. We encourage you to discuss with your doctor any questions or concerns you may have.

Lynn Do, PharmD, Clinical Pharmacist *Updated 5.18.2017*

USED FOR	 Relapsing forms of multiple sclerosis (MS)
	 Teriflunomide will not cure MS. It may reduce flare-ups and slow the disease
	progression.
HOW IT WORKS	Teriflunomide stops immune cells from rapidly growing and multiplying, which
	helps reduce inflammation thought to cause injury to the nervous system from
	MS.
HOW IT IS SUPPLIED	 Teriflunomide 14 mg greenish-blue tablet. Most doctors will not recommend the 7mg tablet as it was not as effective.
	AUBAGIO 14 mg film-costed tablets teriflunomide Oral Intel 28 date canded tablets AUBAGIO 11 reg mental tablets AUBAGIO 11 reg mental tablets AUBAGIO 12 reg mental tablets AUBAGIO 14 mg film manufacture tablets AUBAGIO 14 reg mental tablets AUBAGIO 14 reg mental tablets AUBAGIO 14 reg mental tablets AUBAGIO 15 reg mental tablets AUBAGIO 14 reg mental tablets AUBAGIO 14 reg mental tablets AUBAGIO 15 reg mental tablets AUBAGIO 16 reg mental tablets AUBAGIO 18 reg mental tablets
HOW IT IS GIVEN	Teriflunomide may be taken by mouth with or without food. Take every day at
	the same time of day.
DOSE	One tablet (14 mg) taken by mouth every day
PREGNANCY	If you are a woman and able to become pregnant: You should use effective
WARNINGS	birth control during your Teriflunomide treatment. After you stop Teriflunomide,
	continue using birth control until you confirm your blood levels of Teriflunomide are low enough.
	If you are a man: You and your female partner should use effective birth
	control during your Teriflunomide treatment. After you stop Teriflunomide,
	continue using birth control until you confirm your blood levels of Teriflunomide
	are low enough.
STORAGE	Teriflunomide may be kept at room temperature. Keep the medication away
	from direct sunlight, extreme heat, or cold.

COMMON SIDE	Headache
EFFECTS	Diarrhea
	Nausea
	Hair thinning or loss
	Abnormal liver tests
	If you experience any of these serious side effects, call your doctor right away:
	Symptoms of liver problems such as yellowing of the skin or eye whites,
	nausea, loss of appetite, or dark colored urine
	Numbness or tingling in hands or feet that is different from your MS symptoms
	Symptoms of allergic reaction, including breathing problems, itching, swelling,
	or skin problems such as rash or peeling
DRUG	While you are on Teriflunomide and for at least 6 months after stopping
INTERACTIONS	Teriflunomide, please notify your pharmacist before starting or stopping ANY
	medication. Please also tell your doctors you are on Teriflunomide for MS.
	You should avoid certain vaccines while on Teriflunomide and for 6 months
	after stopping Teriflunomide.
	Teriflunomide can stay in your blood for up to 2 years after stopping the
	medication. Your doctor can prescribe medications such as cholestyramine or
	activated charcoal to lower your blood levels more quickly if needed.
MONITORING	BEFORE starting Teriflunomide, you will need a complete blood cell count,
	lymphocyte subsets, liver function tests, and tuberculosis tests.
	If you are a woman and able to become pregnant, you will need a urine
	pregnancy test. To start Teriflunomide, you must have a negative pregnancy
	test within 1 month with a menstrual cycle. Without a menstrual cycle, you
	must have a negative pregnancy test within 2 weeks.
	AFTER you taken your first dose, you will need to repeat liver function tests
	monthly for 6 months, then annually thereafter. You will need to repeat a
	complete blood cell count annually thereafter. Your blood pressure should also
	be monitored regularly.
MORE	Websites: <u>www.nationalmssociety.org,</u> www.aubagio.com
INFORMATION	Clinical Trials:
	1. O'Connor P, et al. N Engl J Med 2011; 365:1293-1303.
	2. Confavreux C, et al. Lancet Neurol. 2014;13:247-56.